Loncastuximab tesirine
- Generic Name
- Loncastuximab tesirine
- Brand Names
- Zynlonta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1879918-31-6
- Unique Ingredient Identifier
- 7K5O7P6QIU
- Background
Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...
- Indication
Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed Diffuse large B-cell lymphoma NOS, Relapsed High Grade B-cell Lymphoma (HGBCL)
- Associated Therapies
- -
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 6
- Registration Number
- NCT04699461
- Locations
- 🇬🇧
Account University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Virgen del RocÃo, Sevilla, Spain
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 350
- Registration Number
- NCT04384484
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Redlands Community Hospital, Redlands, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 136
- Registration Number
- NCT03684694
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 145
- Registration Number
- NCT03589469
- Locations
- 🇮🇹
U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy
🇮🇹Divisione di Oncoematologia, Milano, Italy
🇬🇧NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.